Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025.. "In the first quarter, we achieved net product ...

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS, the only approved gene therapy for patients with Duchenne ...

Sarepta Therapeutics Inc. (NASDAQ: SRPT) jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company’s experimental gene therapy to treat Duchenne ...

Investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had a good week, as its shares rose 3.3% to close at US$87.11 following the release of its yearly results. The statutory results were mixed ...

Shares of Sarepta Therapeutics SRPT have surged 76.8% in the past three months compared with the industry’s 10.2% rise. Sarepta’s commercial portfolio consists of three RNA-based PMO therapies ...

Sarepta Therapeutics (NASDAQ:SRPT) resumed its recent sell-off on Thursday after Endpoints News reported that the FDA would ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 5.3% resulting in a US$375m addition to the ...

A look at the shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) can tell us which group is most powerful. The group holding the most number of shares in the company, around 84% to be ...

Sarepta Therapeutics (NASDAQ: SRPT), a midcap biotech company, was riding high 18 months ago. The company was awaiting a crucial regulatory approval from the U.S. Food and Drug Administration (FDA ...

We note that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) does have debt on its balance sheet. But the real question is whether this debt is making the company risky. When Is Debt Dangerous?

The stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases ...